B
Bull
Bull · 25%GALT
$3.84
Precio del escenario
$4.020
-0.117 (-2.90%)Al cierre
Loading chart…
- High
- 4.200
- Open
- 4.140
- VWAP
- 4.06
- Vol
- 271.19K
- Mkt Cap
- —
- Low
- 3.950
- Amount
- 1.10M
- EV/EBITDA, TTM
- 0.00
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies.
AI analysis of Galectin Therapeutics Inc (GALT)
buyGalectin Therapeutics Inc (GALT) is a good buy right now due to its recent price momentum and strategic clinical advancements. The current price is $4.02, with a 5-day change of +9.24% and a 20-day change of +35.35%. Despite a wider loss reported in Q2, the company is progressing with its Phase 3 trial design for belapectin, which could enhance its market position. The RSI is at 67.055, indicating strong momentum. However, the main risk is the increasing net loss, which reached $9.11 million in Q2, reflecting ongoing financial challenges.
Analyst Ratings (3)
+173.63% upside
Buy
3 Buy
0 Hold
0 Sell
Current: 4.02
Mínimo
11.00
Promedio
11.00
Máximo
11.00
H.C. Wainwright
Buy
$11
2025-12-17
H.C. Wainwright
2025-12-17
Precio objetivo
$11
Buy
H.C. Wainwright
Buy
$6
2025-06-18
H.C. Wainwright
2025-06-18
Precio objetivo
$6
Buy
HC Wainwright & Co.
Hold
—
2025-04-02
HC Wainwright & Co.
2025-04-02
Precio objetivo
—
Hold
HC Wainwright & Co.
Hold
—
2024-12-27
HC Wainwright & Co.
2024-12-27
Precio objetivo
—
Hold
HC Wainwright & Co.
Strong Buy
$11
2024-11-15
HC Wainwright & Co.
2024-11-15
Precio objetivo
$11
Strong Buy
Métricas de valoración
The current forward P/E ratio for Galectin Therapeutics Inc (GALT) is 4.54, compared to its 5-year average forward P/E of -2.38.
Alphio AI Price Scenarios for GALT
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Cronología de eventos
Noticias
9.508-19NASDAQ.COMGalectin Therapeutics Reports Wider Loss in Q2 Due to Higher Expenses
2.007-14NASDAQ.COMQ32 Bio and Other Biotech Stocks Surge on Positive Trial Results
7.506-25NASDAQ.COMPulsenmore Soars 280% on Ouma Health Collaboration
- 8.506-24NASDAQ.COM
Boundless Bio Merges with Serapha in All-Stock Deal
8.506-23stocktwitsGalectin Therapeutics Reaches Agreement with FDA for Late-Stage Trial
GALT FAQ — answered by Alphio AI
Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Galectin Therapeutics Inc (GALT) is a good buy right now due to its recent price momentum and strategic clinical advancements. The current price is $4.02, with a 5-day change of +9.24% and a 20-day change of +35.35%. Despite a wider loss reported in Q2, the company is progressing with its Phase 3 trial design for belapectin, which could enhance its market position. The RSI is at 67.055, indicating strong momentum. However, the main risk is the increasing net loss, which reached $9.11 million in Q2, reflecting ongoing financial challenges.
3 analysts cover GALT: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.